Indivior Pharmaceuticals, Inc. Cash and Restricted Cash
Indivior Pharmaceuticals, Inc. (INDV) had Cash and Restricted Cash of $222.00 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-03
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $222.00M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $175.00M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $195.00M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $445.00M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $222.00M 10-Q · filed 2026-08-03 |
| 2026-03-31 | $175.00M 10-Q · filed 2026-04-30 |
| 2025-12-31 | $195.00M 10-Q · filed 2026-08-03 |
| 2025-09-30 | $445.00M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $510.00M 10-Q · filed 2026-08-03 |
| 2025-03-31 | $372.00M 10-Q · filed 2026-04-30 |
| 2024-12-31 | $319.00M 10-Q · filed 2026-08-03 |
| 2024-09-30 | $288.00M 10-Q · filed 2025-10-30 |
| 2024-06-30 | $302.00M 10-Q · filed 2025-07-31 |
| 2024-03-31 | $248.00M 10-Q · filed 2025-05-01 |
| 2023-12-31 | $316.00M 10-K · filed 2026-02-26 |
| 2022-12-31 | $774.00M 10-K · filed 2026-02-26 |
| 2021-12-31 | $1.10B 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |